On April 13, 2023 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 26, at 4:30 p.m. ET to discuss first-quarter 2023 financial results and provide a general business update (Press release, BioMarin, APR 13, 2023, View Source,-April-26,-at-4-30pm-ET [SID1234630033]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dial-in Number
U.S. / Canada Dial-in Number: 800-831-4163
International Dial-in Number: 213-992-4616

U.S. / Canada Replay Dial-in Number: 800-645-7964
International Replay Dial-in Number: 757-849-6722
Playback ID: 9184#

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.

On April 13, 2023 Bio-Techne Corporation (NASDAQ: TECH) reported it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), taking place April 14-19 in Orlando, Florida (Press release, Bio-Techne, APR 13, 2023, View Source [SID1234630032]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bio-Techne’s booth (#1763) will feature its wide range of products, services and capabilities that enable cancer research and discoveries as well as cell and gene therapy development and workflow solutions including its industry leading portfolio of reagents, immunoassays, proteomic analytical instruments, spatial biology solutions and companion diagnostics capabilities. Additionally, several scientists from the Company will present posters with updates on biomarkers of therapeutic benefit, structural and chemical biology, and spatial biology.

"I am excited to highlight our broad portfolio of tools, reagents and workflow solutions that enable cancer research at this important conference," commented Chuck Kummeth, President and CEO of Bio-Techne. "Bio-Techne’s portfolio plays a critical role in the discoveries that further the scientific communities’ understanding of cancer and other diseases, enabling the development of next-generation treatments and therapies, including the emerging class of cell and gene therapies. I am proud of the impact our Company has on research and ultimately improving the lives of patients around the globe."

Poster Presentations:

An exosome-based ESR1 monitoring RT-qPCR technology that rapidly and accurately detects circulating tumor acquired resistance variants at ≤0.1% frequency in liquid biopsy samples
Tuesday, April 18th from 9:00 AM – 12:30 PM EDT
Presenter: Gary Latham, Ph. D.
Section 37, Poster Board #29, Abstract #4354

Development of p300-targeting PROTACs with enhanced selectivity and onset of degradation
Tuesday, April 18th from 9:00 AM – 12:30 PM EDT
Presenter: Hannah Maple, Ph. D.
Section 14, Poster Board #3, Abstract #3841

Multiomic spatial analysis with simultaneous detection of small RNAs, mRNAs and proteins using the novel RNAscope Plus Technology
Tuesday April 18th from 9:00 AM – 12:30 PM EDT
Presenter: Sayantani Basak, Ph. D.
Section 11, Poster Board #7, Abstract #3775

Interrogating the tumor-immune landscape with a novel automated RNAscope assay for multiplexed detection of RNA and protein
Wednesday, April 19 from 9:00 AM – 12:30 PM EDT
Presenter: Anushka Dikshit, Ph. D.
Section 43, Poster Board #11, Abstract #6771

Poster in Collaboration Presentations:

Application of a multiplex urinalysis test for predicting treatment response in patients with BCG unresponsive bladder cancer: a pilot study
Tuesday, April 18th from 1:30 PM – 5:00 PM EDT
Presenter: Hideki Furuya, Ph. D.
Section 37, Poster Board #6, Abstract #5456

On April 13, 2023 Ascendis Pharma A/S (Nasdaq: ASND) reported that the company will hold a conference call and live webcast on Thursday, April 27, 2023, at 4:30 p.m. Eastern Time (ET) to review its first quarter 2023 financial results and provide a business update (Press release, Ascendis Pharma, APR 13, 2023, View Source [SID1234630031]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at View Source A replay of the webcast will be available on this section of our website shortly after conclusion of the event for 30 days.

On April 13, 2023 IUCT-Oncopole reported to launch an ambitious national project in collaboration with Artios Pharma Limited (Artios), a clinical stage biotech company pioneering the development of novel small molecule therapeutics that target the DNA damage response ("DDR") process to unravel the mechanisms of resistance to anti-PARP therapies in patients with metastatic breast cancer with germline mutations of the BRCA1 and/or 2 genes (Press release, Artios Pharma, APR 13, 2023, View Source [SID1234630030]). Entitled REPARP (REpair factor expression as biomarker of PARP inhibitor resistance), its ambition is to deliver medicines that improve the survival of these patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New ways to combat poor prognosis in breast cancer

Metastatic cancer occurs when the disease (tumour) has spread from the breast and local lymph nodes to other parts of the body (metastasis), such as the bones, liver or lungs. Fewer than 10% of breast cancers are metastatic at the time of diagnosis, but it is estimated that 15-20% of patients with early diagnosed breast cancer will go on to develop metastases. The aim of current metastatic treatments is to slow down the progression of a disease that unfortunately cannot be cured. Poly ADP-ribose polymerase (PARP) inhibitors are a promising new class of molecules and are prescribed alone or in combination with hormone therapy for breast cancer. This targeted therapy has reduced the risk of relapse in patients with a BRCA1 and/or 2 mutation in both the metastatic and early stages. However, at the metastatic stage, some patients present a disease that is resistant to this treatment from the outset or eventually develop resistance, i.e. their disease progresses despite the treatment.

BRCA1 and BRCA2 play a major role in a pathway for repairing chromosomal breaks known as homologous recombination. They act like ‘mechanics’ in our cells. In the case of BRCA1 and/or 2 mutations, this repair pathway is impaired. PARP inhibitors act by increasing the rate of breaks leading to tumour cell death. PARP is a major player in the alternative DNA repair pathways used by cancer cells for survival in the case of BRCA1 and/or 2 mutations.
Recent laboratory studies suggest that tumour cells resistant to PARP inhibitors set up another alternative repair pathway mediated by the DNA Polymerase or POLQ, which acts as a substitute ‘mechanic’. POLQ inhibitors being developed by Artios (Phase I underway; NCT04991480) could prevent or treat this resistance to PARP inhibitors.

The IUCT-Oncopole’s and Artios’ expertise in translational research underpins the REPARP project.

The REPARP project consists of using tumour and fluid samples (blood samples) taken at different times during treatment with PARP inhibitors to explore whether the POLQ repair pathway is established and is associated with therapeutic resistance. This would allow the identification of patients who could
benefit from further treatment with POLQ inhibitors. The aim is to include 120 patients throughout the 25 national centres participating in the study. Results are expected in three years.

"PARP inhibitors have significantly improved the treatment of cancers, but long-term use can often lead to resistance that is challenging to overcome," said Prof. Florence Dalenc Department of Medical Oncology The IUCT-Oncopole. "Analyzing tumour samples can help us better understand why some patients experience a lack of efficacy to PARP inhibitors. These learnings can help improve treatment decisions for different patient types and help determine potential drug combinations with synergistic activity that can restore sensitivity to PARP inhibition."

Prof. Florence Dalenc (Department of Medical Oncology), and Drs. Jean-Sébastien Hoffmann and Camille Franchet (Department of Anatomy and Pathologic Cytology – CHU de Toulouse, directed by Prof. Pierre Brousset) are coordinating this study. Pathological and imaging analyses are carried out by the Imag’IN platform (View Source) coordinated by Drs. François-Xavier Frenois and Nathalie Van Acker. The translational part on liquid biopsy (obtained from blood) is undertaken by the team directed by Dr. Anne Pradines (Laboratory of Oncological Medical Biology) and is funded by the National Cancer Institute (INCa).

The translational and bioinformatics team at Artios, led by Dr. Sarah Holt and Dr. Suraj Menon respectively, will also be heavily involved in the analysis of the liquid and tumour biopsy samples using the Artios DcoDeR Platform.

On April 13, 2023 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, reported that it will participate in four upcoming investor conferences (Press release, Allogene, APR 13, 2023, View Source [SID1234630029]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Canaccord Genuity – CG Horizons in Oncology Virtual
Thursday, April 20, 2023
8:00AM PT/11:00AM ET

BofA Securities 2023 Health Care Conference
Wednesday, May 10, 2023
4:20PM PT/7:20PM ET

The JMP Securities Life Sciences Conference
Monday, May 15, 2023
8:30AM PT/11:30AM ET

2023 RBC Capital Markets Global Healthcare Conference
Tuesday, May 16, 2023
1:35PM PT/4:35PM ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.